Penumbra, Inc. is a healthcare company that designs, develops, produces, and distributes innovative medical devices globally. With its headquarters in Alameda, California, the company was founded in 2004. Penumbra concentrates its efforts on creating and expanding its broad product range, which includes aspiration-based thrombectomy systems, embolization coiling systems to treat patients with aneurysms, and neurological access systems to provide intracranial access, among other therapies, as well as a virtual reality platform.
The company's extensive line of devices targets serious medical diseases in areas with considerable unmet need. Selling products to over 100 countries, Penumbra works through direct sales organisations as well as distributors, helping to supply healthcare practitioners, hospitals, and clinics in the United States, Europe, Canada, Australia, and more. Penumbra’s neuro products include aspiration-based thrombectomy systems and accessory devices such as the Penumbra System, which consists of revascularization devices designed to provide mechanical thrombectomy.
Penumbra stock can be found on the NYSE, where it trades under the ticker PEN. In November 2021, the company announced promising results on the performance of its Indigo® System CAT RX catheter used in patients at high risk for acute coronary syndrome.
Keep an eye on the price movements of PEN stock by adding it to your eToro watchlist.